ADULT BONE AND MINERAL WORKING GROUP
Additional Registration Fee: $30
Case Discussion on Bone and Mineral Metabolism
In the field of bone and mineral metabolism, case discussions hold immense visionary significance as they foster innovation, collaboration, and transformative breakthroughs in understanding and managing complex skeletal disorders. These discussions serve as catalysts for knowledge exchange, driving the identification of rare bone conditions, unveiling novel treatment approaches, and elucidating underlying pathophysiological mechanisms.
By sharing unique clinical experiences, challenging diagnostic dilemmas, and successful treatment strategies, case discussions empower clinicians and researchers to expand the boundaries of their expertise. Through collaborative analysis and collective brainstorming, these discussions promote critical thinking, enhance problem-solving skills, and stimulate the generation of innovative hypotheses.
Case discussions in the bone and mineral metabolism field have the potential to revolutionize patient care. By elucidating intricate disease presentations, they enable early recognition and accurate diagnosis of rare bone disorders, paving the way for personalized treatment interventions.
In an era of rapid scientific advancements, case discussions provide an invaluable platform for sharing experiences, disseminating knowledge, and driving scientific progress. They fuel the advancement of evidence-based guidelines, shape future research priorities, and inspire the next generation of bone and mineral metabolism experts.
In summary, visionary case discussions in the bone and mineral metabolism field have the transformative power to reshape our understanding of skeletal disorders, revolutionize patient care, and pave the way for innovative therapies. By fostering collaboration, inspiring innovation, and driving scientific progress, these discussions play a pivotal role in shaping the future of bone and mineral metabolism research and clinical practice.
Yumie Rhee, MD, PhD
Department of Internal Medicine, Endocrine Research Institute
Yonsei University College of Medicine, Seoul, Korea
Aliya Khan, MD, FRCPC, FACP, FACE
Professor of Clinical Medicine, Divisions Endocrinology and Geriatrics
McMaster University, Bone Research & Education Centre, Canada
Kassim Javaid, MD
Lecturer in Metabolic Bone Disease, Honorary Consultant Rheumatologist, Greater Oxford Area
Lecturer in Metabolic Bone Disease, Honorary Consultant RheumatologistLecturer in Metabolic Bone Disease, Honorary Consultant Rheumatologist
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK
7:30 pm Opening Remarks and Dinner
8:00 pm Progressive metaphyseal deformities and sclerosis in 11 year fraternal twins with Osteosclerotic metaphyseal dysplasia (OSMD) and Hypophosphatasia (HPP)
Nancy Street Dunbar, MD, MPH, FAAP
University of Connecticut School of Medicine, USA
8:15 pm The Use of Ketoconazole for Hypercalcemia Resulting from Lymphoma
Katlyn Sawyer, MD
University of Colorado, USA
8:30 pm Successful management of sarcoid-mediated hypercalcemia with anti-TNF-alpha antibody adalimumab
Aidar R. Gosmanov, MD, PhD, FACE
Albany Medical College, Stratton VA Medical Center, USA
8:45 pm Pregnancy and hypoparathyroidism
Dalal Ali, MD, FRCPI
McMaster University, Canada
9:00 pm Boy Frame Award: Cyrus Cooper, MBBS, DM, FRCP, FFPH, FMedSci
Professor of Rheumatology and Director of the MRC Lifecourse Epidemiology Unit; Vice-Dean of Medicine at the University of Southampton; and Professor of Musculoskeletal Science at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford
9:05 pm Special Lecture: Steven R. Cummings, MD,
Director, San Francisco Coordinating Center
Research Scientist, California Pacific Medical Center Research Institute
Professor of Medicine, Epidemiology and Biostatistics, Emeritus
University of California, San Francisco
Epidemiology: A Foundation for Clinical Trials of our Treatments to Prevent Fracture
9:30 pm Concluding Remarks
Disclosures: Dr. Aidar R. Gosmanov – AbbVie, 2, Dr. Steven R. Cummings – Amgen, 5, Dr. Dalal Ali - Nothing to disclose.